Hansa Biopharma

Description

Hansa Biopharma develops immunomodulating antibody-cleaving enzyme therapies that target and inactivate IgG antibodies, inhibiting IgG-mediated immune responses for autoimmune diseases, gene therapy desensitization, and transplantation desensitization.

Hansa Biopharma is located in the Copenhagen ecosystem.

Related

• TTolerogenixxTolerogenixx develops personalized therapies using proprietary modified immune cell technology to target immune modulation, including…
• SciRhomSciRhom develops humanized antibodies against iRhom2 that selectively inhibit TACE in immune cells, blocking TNF-alpha, IL-6, and HB-EGF…
• AAsgard TherapeuticsAsgard Therapeutics develops AT-108, an off-the-shelf gene therapy using direct cell reprogramming to activate professional…
• ActiTrexxActiTrexx develops therapies based on activated regulatory T cells for autoimmune and autoinflammatory diseases, including ATreg/Actileucel…
• TQ TherapeuticsTQ Therapeutics operates a CELLfinity platform that delivers in vivo cell and gene therapies using a proprietary EXiVO automated approach…
• NETRIS PharmaNETRIS Pharma develops therapeutics that target Netrin-1 to overcome resistance to oncology treatments, producing monoclonal antibodies…
• Oy Medix BiochemicaOy Medix Biochemica supplies diagnostic raw materials, including monoclonal and polyclonal antibodies, native and recombinant antigens,…
• CimCureCimCure develops cancer vaccines using its proprietary iBoost conjugate technology to induce immune responses that target and destroy…
• SyngensysSyngensys develops synthetic gene promoters using transcriptional landscape analysis, computational design, selection, and validation to…